Amneal Pharmaceuticals, Inc. Q3 FY2024 earnings call

• Collaboration and GLP-1 Entry: Partnership with Metsera to enter the global obesity space, building 2 new GLP-1 manufacturing facilities. - Product Launches: Launched CREXONT for Parkinson's disease, with positive patient feedback; extended release Pyridostigmine Bromide approved for military use; DHE auto injector for migraines on track. - Operations: Focus on quality, automation, digitization, and AI in operations; addressing drug shortages, especially injectables. - Innovation: Continued R&D in complex generics, injectables, biosimilars, and inhalation, with a strong pipeline of pending approvals.

In the third quarter, revenues grew 13% to $702 million. The generics (affordable medicines) business grew 9% to $427 million, driven by new product launches and biosimilars contributing $31 million. The specialty segment saw revenues grow 19% to $116 million, led by branded products with the Parkinson's franchise (including CREXONT, Rytary, ONGENTYS) delivering $61 million. The outcare business grew 21% to $159 million, reflecting growth in distribution and government channels.

Management expects continued growth in 2025 from topline, bottom line, and cash generation. Biosimilars, healthcare distribution, injectables, and CREXONT are key growth drivers. Anticipate reduced interest expense due to debt reduction. Plans to leverage infrastructure and capabilities in the GLP-1 space for future growth.

• Drug Shortages: Ongoing challenge in the U.S. for injectables, though Amneal is working to address this. - Rytary Loss of Exclusivity: Potential impact on revenue, but offset by growth in other segments like CREXONT.

Q: Discuss reimbursement landscape for CREXONT, especially Part D, and adoption in context of Rytary's LOE.

A: CREXONT has good initial coverage, expected to have broader access than Rytary, with no major impact from Rytary's LOE as it expands the market.

Q: Injectable mix of shortage products and complex products.

A: Injectable portfolio is balanced with complex products driving revenue, and capabilities to address shortages.

Q: GLP-1 partnership financials, CapEx, and longer-term goals.

A: Metsera provides $100 million for CapEx, net expense within budget, setting up for global supply of peptides-based products.

Q: Business development landscape, biosimilars opportunity, and 2025 outlook.

A: Focus on specialty products and biosimilars, with biosimilars seen as a key growth area. 2025 expected to be strong with continued growth.